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Abstract
Background: In 2001, the Institute of Medicine’s (IOM) report, “Exploring the Biological Contributions to Human
Health: Does Sex Matter?” advocated for better understanding of the differences in human diseases between the
sexes, with translation of these differences into clinical practice. Sex differences are well documented in the
prevalence of cardiovascular (CV) risk factors, the clinical manifestation and incidence of cardiovascular disease
(CVD), and the impact of risk factors on outcomes. There are also physiologic and psychosocial factors unique to
women that may affect CVD risk, such as issues related to reproduction.
Methods: The Society for Women’s Health Research (SWHR) CV Network compiled an inventory of sex-specific
strategies and methods for the study of women and CV health and disease across the lifespan. References for
methods and strategy details are provided to gather and evaluate this information. Some items comprise robust
measures; others are in development.
Results: To address female-specific CV health and disease in population, physiology, and clinical trial research, data
should be collected on reproductive history, psychosocial variables, and other factors that disproportionately affect
CVD in women. Variables related to reproductive health include the following: age of menarche, menstrual cycle
regularity, hormone levels, oral contraceptive use, pregnancy history/complications, polycystic ovary syndrome
(PCOS) components, menopause age, and use and type of menopausal hormone therapy. Other factors that
differentially affect women’s CV risk include diabetes mellitus, autoimmune inflammatory disease, and autonomic
vasomotor control. Sex differences in aging as well as psychosocial variables such as depression and stress should
also be considered. Women are frequently not included/enrolled in mixed-sex CVD studies; when they are included,
information on these variables is generally not collected. These omissions limit the ability to determine the role of
sex-specific contributors to CV health and disease. Lack of sex-specific knowledge contributes to the CVD health
disparities that women face.
Conclusions: The purpose of this review is to encourage investigators to consider ways to increase the usefulness
of physiological and psychosocial data obtained from clinical populations, in an effort to improve the understanding of
sex differences in clinical CVD research and health-care delivery for women and men.
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Background
Despite cardiovascular disease (CVD) being a major
health-care burden and the leading cause of death in
women and men in the USA, marked disparities in
cardiovascular health persist between the sexes [1, 2].
Indeed, more women die annually from CVD compared
with men [3]. While some studies have shown an im-
provement of CV outcomes in women versus men over
time [3–5], others have not [6, 7]. In particular, CVD
mortality is increasing in women between the ages of 35
and 54 years [8]. The reasons for this increase are con-
troversial and reflect our limited understanding of the
sex differences in physiology between women and men,
which is substantially related to lack of female-specific
data.
The recognition of sex differences in the pathophysi-
ology and the expression of human disease, including
CVD, led to the NIH mandate to include both women
and men in clinical studies and trials and to analyze data
by sex [9]. However, the number of identified variables
contributing differentially to CVD outcomes in women
and men is large and growing. Variables that influence
CVD risk include sex chromosomes [10], hormonal status
[11], disorders related to reproduction and pregnancy
[12], aging, and sex and gender-specific psychological or
psychosocial variables [13, 14]. Many of these variables are
not considered during the design of clinical trials or longi-
tudinal cohort studies, which reduces the ability to deter-
mine sex-specific contributors to health and disease. The
lack of inclusion of sex-specific data collection also limits
the ability to analyze sex differences.
The purpose of this review is to highlight variables
that may contribute to our understanding of CVD in
women (Table 1). We will also outline strategies and
methods used in population, physiological/translational,
and clinical trial research that will enable the optimization
of CVD investigation and outcomes in women.
Population research
Population research provides a unique opportunity to
gather information that allows comparison of both trad-
itional and novel CVD risk factors by sex. Previous re-
views from our group and others have discussed sex and
gender differences in CVD risk but have not provided
guidelines for the collection of data that could expand
beyond traditional risk factors [15–18]. For example, in
addition to the commonly collected demographic vari-
ables, population researchers should consider including
hormonal characteristics [19], sex hormonal status,
pregnancy-related disorders [12], polycystic ovary syn-
drome (PCOS) [20], and psychosocial issues such as de-
pression [21], abuse and domestic violence [22, 23], and
post-traumatic stress disorders (PTSDs). Including this
information in appropriate databases will expand the
scientific understanding of the contribution of sex-
related variables to sex differences in clinical CVD and
increase knowledge about CVD in women and men.
Data collection methods are discussed in below.
Hormonal status
Altered menstrual patterns are a readily identifiable indi-
cator of potential hypoestrogenism and other neurohor-
monal alterations. However, the causes of altered
menstrual patterns are many and include both ovarian
and nonovarian causes. Common ovarian causes include
the following: (1) polycystic ovary syndrome, sometimes
referred to as hyperandrogenic anovulation; (2) prema-
ture ovarian insufficiency which is due to reduced or ac-
celerated loss of oocytes and is often accompanied by
autoimmune disorders such as juvenile diabetes and
autoimmune thyroiditis and by chromosomal abnormal-
ities such as 45,XO or 46,XX/45,XO mosaicism or
microdeletions within the long arm of the X chromo-
some; (3) stress-induced hypogonadism, which is
accompanied by a constellation of neuroendocrine
aberrations including hypercortisolism and hypothalamic
hypothyroidism; (4) syndromal psychiatric syndromes
such as depression, schizophrenia, and eating disorders,
including anorexia nervosa and bulimia, which may alter
neuroendocrine function and result in hypothalamic
hypogonadism; (5) other systemic medical conditions and
disorders including thyroidal conditions, hyperprolactine-
mia, and adrenal disorders to name but a few; (6) environ-
mental and other unintentional exogenous hormonal
exposures; (7) hormone use such as oral contraceptives;
(8) drug use and abuse, including alcohol, marijuana, and
opiates; (9) medications including antipsychotics and
neuroleptics, selective estrogen receptor modulators
(clomiphene, tamoxifen, raloxifene), and aromatase inhibi-
tors; and (10) food-based phytoestrogens.
Women with eating disorders also often have severe
nutritional compromise and significant hypercortisole-
mia, which may further accelerate CVD risk. There is a
paucity of studies on the long-term health of women
with all forms of hypothalamic hypogonadism. Greater
investigative attention has been given to women with
polycystic ovary syndrome due to accompanying features
of metabolic syndrome
Sex differences in the molecular and physiological re-
sponses to common hormones such as cortisol and thy-
roid hormones likely contribute to differences in risk for
stress-induced cardiovascular disease to as great an ex-
tent as hypogonadism. While stressors produce hypo-
thalamic hypogonadism in both women and men, with
attendant reductions in sex-specific hormones such as
estradiol and progesterone in women and testosterone
in men, the events that trigger stressful reactions differs
between sexes and comparable stressors elicit different
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types or different magnitude responses in men and
women [24]. Women may be more sensitive to certain
types of psychosocial stressors than men while men ap-
pear to be more sensitive to metabolic stressors such as
undernutrition than women [25–27]. During lactation,
women are much less sensitive to metabolic stressors [28].
Furthermore, while stressors increase cortisol secretion in
women and men, the molecular signature and other ef-
fects of cortisol upon various tissues differ by sex [29].
Cortisol antagonizes the physiological actions of estrogen
through co-regulation of the same molecular pathways,
suggesting that stress-induced hypogonadism cannot be
counteracted by hormone replacement regimens that sim-
ply supply the missing gonadal hormones [30].
Findings from the Women’s Ischemic Syndrome
Evaluation (WISE) study suggest that endogenous estro-
gen deficiency in young women may be a potent risk
factor for atherosclerosis. While both primary ovarian
insufficiency due to reduced oocyte count and/or accel-
erated atresia and acquired, stress-induced, ovulatory
disruption result in estrogen deficiency, the latter is the
most prevalent and most studied in premenopausal
women. Premenopausal women with stress-induced sup-
pression of the central drive of gonadotropic-releasing
hormone (GnRH) may develop anovulation and amenor-
rhea or continue to have menstrual cycles but with re-
duced estradiol and progesterone secretion. Not only
does stress have the potential to cause hypoestrogenemia,
Table 1 Variables affecting women across their lifespan
I. Reproductive health
Hypoestrogenemic conditions Polycystic ovarian syndrome is associated with vascular changes [20, 229, 230]
Stress reduces pituitary LH and FSH secretion leading to anovulation and secondary
hypoestrogenemia [31, 32].
Pregnancy hypertension A women’s recall of pregnancy hypertensive disorders is specific but sensitivity varies and
the positive predictive value is low [65]. Investigators have suggested standardization of
study design for research involving women with preeclampsia [231]
Maternal/fetal exposure to other pregnancy disorders Women with histories of preeclampsia, gestational diabetes, small-for-gestational-age
deliveries, or preterm deliveries (whether spontaneous or medically indicated) are at about
twofold the increased risk of coronary heart disease and stroke compared with women
who have had pregnancies uncomplicated by these factors [12]
Microchimerism Fetal cells passage transplacentally into the maternal circulation during pregnancy and
persist for decades (this is termed fetal microchimerism or FMC). FMC is potentially
associated with detrimental effects, e.g., preeclampsia and autoimmune disease, and with
beneficial effects, e.g., female longevity due to regeneration and repair due to FMC. FMC
has been identified in explanted idiopathic cardiomyopathy hearts [77] and the frequency
and concentration are higher in women with preeclampsia [78, 232]
Early menopause Associated with greater coronary artery disease and stroke risk [58]
II. Sex hormones
Endogenous sex hormones Sex hormone levels are associated with body composition, incident diabetes, and other
risk factors [233].
Hormone therapy and age of therapy Sub-analyses from Women’s Health Initiative indicate age of hormone therapy (HT) may
impact risk/benefit. The KEEPS trial showed no difference in progression of carotid
intima-media thickness in women treated early post-menopause with oral or transdermal
estrogen [46]
III. Psychosocial issues
Depression More common in women and associated with incident CVD and worse prognosis
[234, 235]. The AHA has recognized depression as a risk factor for poor prognosis among
patients with acute coronary syndrome [236]
Stress Reduces pituitary LH and FSH secretion leading to anovulation and secondary
hypoestrogenemia [31, 32]
Elderly age Women are the majority of the elderly with high burden of CVD [161]
IV. Other variables
Impact of diabetes DM confers greater risk in women than men [171]
Non-atherosclerotic coronary disease Vasomotor dysfunction and coronary microvascular disease are often not considered
despite women having lower prevalence of obstructive CAD [34]
Inflammatory autoimmune disease Rheumatologic disorders, particularly systemic lupus erythematosus and rheumatoid
arthritis, are more prevalent in women and are associated with more prevalent
CVD [176, 237, 238]
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it also increases cortisol, which blocks estrogen action.
Hypoestrogenemia of hypothalamic origin (defined as
estradiol <184 pmol/l (50 pg/ml), FSH <10 IU/l, and
luteinizing hormone <10 IU/l) was the most powerful in-
dependent predictor of angiographic coronary artery dis-
ease (CAD) such that in women with suspected ischemia,
those with hypothalamic hypogonadism were at sevenfold
(odds ratio = 7.4, 95 % CI of 1.7 to >30) increased risk of
obstructive atherosclerotic CAD at coronary angiography
[31]. Extension of this work suggests that diabetes and
environmental stress may contribute to hypothalamic
hypoestrogenemia with simultaneous involvement of
other neuroendocrine systems [32] and inflammatory and
oxidative stress mechanisms [33]. Additional studies from
WISE have documented a protective association between
prior oral contraceptive use during the premenopausal
years and postmenopausal atherosclerosis, measured by
coronary artery disease severity scores at angiography
[34]. These findings combined with prior literature sug-
gest that premenopausal estrogen deficiency due to ovar-
ian dysfunction may be a potent risk for cardiovascular
disease and may explain the more adverse prognosis expe-
rienced by premenopausal women compared to age-
matched men with cardiovascular disease. However, since
stress-related hypothalamic hypogonadism and other
causes of hypogonadal dysfunction occur in both men and
women, more research is needed to determine if there are
sex differences in the frequency of hypothalamic forms of
hypogonadism or if hypogonadism is more deleterious in
women than in men.
Recognizing and diagnosing the cause of altered
menstrual cycle function is rarely straightforward. The
association between hypogonadism and cardiovascular
disease may vary according to the etiology. In addition,
alterations in cyclic ovarian function may affect nonre-
productive tissues [35].
Methods for characterizing gonadal function
The first step in detecting altered ovarian function is to
screen for alterations in or persistently abnormal men-
strual bleeding patterns. There are many causes of ab-
normal uterine bleeding. An evaluation of abnormal
uterine bleeding (AUB) must determine the presence or
absence of endometrial and cervical polyps, fibroids, ma-
lignancy, coagulopathy, endometrial infection, adhesions,
and scarring, and exogenous exposure, known and un-
known, to hormones and hormonal mimetics [36]. Once
the above causes have been excluded, the next step is to
determine the presence or absence of ovulation and
ovarian dysfunction. Ovarian patterns can be classified
as fully ovulatory, anovulatory, and luteal insufficiency.
There is a spectrum of ovarian function ranging from
fully ovulatory to fully anovulatory. The intermediate
states are the most difficult to identify, characterize, and
result from a combination of wavering hypothalamic
GnRH drive and varying oocyte quality. If ovarian dys-
function is identified, the cause must then be sought.
Functional hypothalamic hypogonadism is likely the
most common cause of AUB and amenorrhea, but it is a
diagnosis of exclusion. To make matters more complex,
ovarian function changes with age as the egg reserve di-
minishes and oocyte responses become increasingly less
predictable. Classification schemes such as Stages of
Reproductive Aging Workshop (STRAW) aim to parti-
tion the transition from normative ovarian function to
menopause but cannot fully define an individual
woman’s endogenous hormonal exposures [37]. The lack
of a simple, robust methodology for classifying ovarian
function and dysfunction is intrinsic to the reproductive
system and likely explains, at least in part, the lack of
clarity about the contribution of sex hormones to car-
diovascular health.
Strategies exist for characterizing alterations in go-
nadal function, but most of the strategies require serial
blood or urine samples taken across a defined time
frame often defined pragmatically as the interval be-
tween the day of first menstrual bleeding and the day of
the next first menstrual bleeding. When menstrual cy-
cles occur with predictable regular intervals, a single
blood sample that is appropriately timed can allow
gonadal function to be estimated [35]. For instance,
in women whose menstrual cycle interval is regularly
27–31 days, the presence or absence of ovulation can
be easily monitored with (1) over-the-counter urinary
LH surge detector kits and (2) measuring progester-
one during the midluteal phase (days 20–23 from the
day of the first menses) or day +7 after LH surge. A
progesterone >10 ng/ml is considered “fully ovulatory,” a
level <1 ng/ml signals anovulation, and an intermediate
value indicates luteal insufficiency. How often to sample
blood, saliva, urine, or any other bodily tissue depends on
the need to accurately define ovarian function. The more
frequent the sampling, the greater the accuracy of assess-
ment but the greater the subject burden and investigator
cost. The gold standard for measurement of sex steroids
such as testosterone and androstenedione in the
blood or other tissue is liquid chromatography linked
with mass spectroscopy. This method reduces the
possibility of measuring similar steroids (greater
specificity) and allows for greater sensitivity. This
method may not be cost-effective or feasible in all re-
search or clinical environments, although it is becoming
more affordable and more widely available [38, 39]. Vari-
ous immunoassay methodologies are commercially avail-
able [38, 40, 41]. Figure 1 provides an algorithm for
assessing ovarian function.
In the systemic circulation, sex hormone-binding
globulin (SHBG) binds sex steroids with greater affinity
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for testosterone than estrogen. This buffering mechanism
keeps hormonal excursions within a given range. This
mechanism does not seem to operate in the cerebrospinal
fluid (CSF). Hormones, especially cortisol, in CSF are not
protein bound to any significant degree, thus if hormone
levels are measured in CSF, it should be recognized that
these are free (bioactive) levels [42].
One potential way to mitigate the problems associated
with the determination of circulating hormones is to as-
sess such hormone concentrations in conjunction with
measurement of menstrual patterns including interval
between bleeding episodes and perceived flow (heavy,
light, long, spotting, etc). One precautionary note is that
measurement of hormones in the circulation, urine, or
saliva may not be reflective of the active hormone level
at the tissue or cellular level because of the local metab-
olism of the sex steroids. Many organs outside of the re-
productive organs contain receptors for sex steroids and
the exact action of sex steroids upon the various tissues
of relevance are determined by tissue-specific mecha-
nisms that may themselves differ in males and females
[43]. Furthermore, interpretation of hormonal levels
should be considered as the proximate integration of
neuroendocrine patterns occurring at the hypothalamic
level in response to central and peripheral signals. Thus,
neuroendocrine function is coordinated and integrated
such that there is no such condition as isolated ovarian
dysfunction. Further, primary glandular diseases such as
autoimmune thyroiditis alter ovarian function and com-
promise ovulation. The complexity is often frustrating
for clinical investigators hoping for simple classification
schemes.
Methods to identify reproductive and menopausal status
Debate continues as to whether menopausal status im-
pacts CVD, e.g., whether observed relations are predom-
inantly due to aging [44], to perimenopausal changes in
sex hormone level status (beneficial, detrimental, or
neutral) [11, 45], or to exogenous administration of sex
hormones [46, 47]. Notably, sex differences in CV health
and disease are present throughout the entire human
lifespan not only during menarche and menopause [48].
Clearly, defining sex-specific hormonal status is crucial
to the investigation into understanding CVD in women.
Menopausal status can be defined by changes in a
woman’s menstrual bleeding as in the Massachusetts
Women’s Health Study [49], the Study of Women’s
Health across the Nation (SWAN), and the WISE study
[50], among other epidemiologic studies. Following the
Massachusetts Women’s Health Study [51–55], SWAN
defines four menopausal status categories: Premeno-
pausal, less than 3 months of amenorrhea and no in-
crease in menstrual irregularity in the past year; Early
perimenopausal, less than 3 months of amenorrhea with
some increase in menstrual irregularity; Late perimeno-
pausal, between 3 and 11 months of amenorrhea;
Postmenopausal, 12 or more consecutive months of
amenorrhea with no medical cause other than menopause.
SWAN classifies women who have had a hysterectomy or
a bilateral salpingo-oophorectomy (BSO) as surgical
menopausal, a separate category from women who are
naturally postmenopausal. The term “hysterectomy”
needs to be carefully defined as the removal of the
uterus only with preservation of the ovarian tissue as
not the same as the removal of the uterus and one or
Cycle interval regularly 27-31 days? 
YES
Measure midluteal (cycle day 
20-23) progesterone
10 ng/ml = fully ovulatory
1-10 ng/ml = luteal insufficiency
1 ng/ml = anovulation (see right text 
box for adjudication)
NO
Measure LH, FSH, estradiol (E2), progesterone (P), TSH, 
total thyroxine, prolactin, androstenedione
PCOS
LH and FSH normal and LH:FSH
E2 30-100 pg/ml, P < 1 ng/ml
Androstenedione > 200 ng/dl
Perimenopause
LH and FSH elevated, E2 < 50 pg/ml, P <1 ng/ml
Hypothalamic Hypogonadism
LH and FSH low or normal, FSH > LH
E2 <50 pg/ml, P < 1 ng/ml
Hypo- and Hyperthyroidism – see standard 
criteria
Hyperprolactinemia – see standard evaluation
Fig. 1 Algorithm on assessment of ovarian function
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two ovaries when residual ovarian function is a relevant
variable. The WISE study developed an algorithm using
menstrual, surgical, and reproductive history with serum
hormone assays [50]. In 2011, the STRAW [37] suggested
a staging system (STRAW+ 10) that incorporated more
recent data on hypothalamic-pituitary-ovarian function
that occurs before and after the final menstrual period
may be ideal [37, 50]. The type of hysterectomy (degree of
ovarian preservation) or of menopause and the age of
menopause have been associated with differences in risk
factors and cardiovascular risk [56–58]. Therefore, these
demographic data should be carefully documented in clin-
ical trial intake information, inclusion, and exclusion
criteria.
Pregnancy-related disorders
One of the most obvious sex differences for medical re-
search is pregnancy. While parity has been extensively
studied with respect to CVD, newer research is begin-
ning to link several pregnancy complications to in-
creased CVD risk. While there is abundant correlative
data of reproductive health with CVD, data are lacking
regarding whether reproductive complications cause
CVD. Even if the associations of pregnancy complica-
tions with CVD do not prove to be causal, they can
serve as useful early warnings of rate of progression of
subclinical to symptomatic CVD. For example, both the
American Heart Association (AHA) and American
College of Obstetricians and Gynecologists (ACOG)
guidelines now include a history of preeclampsia as a
CVD risk factor [59, 60]. The lack of comprehensive
CVD and reproductive phenotyping in studies of women
is a barrier to fully understanding the intimate connec-
tions between reproductive health/disorders and CVD;
both fields would benefit from closer engagement and
each should be considered in evaluating a woman’s CVD
risk. Validity of data collected by medical records and
through participant recall is discussed below.
The connections between pregnancy complications
and CVD outcomes have been reviewed elsewhere [12].
In brief, women with a history of preeclampsia,
gestational diabetes, small-for-gestational-age (SGA) de-
liveries, or preterm deliveries (whether spontaneous or
medically indicated) are at about twofold the increased
risk of coronary heart disease and stroke compared with
women who have had pregnancies uncomplicated by
these factors. Relative risks are graded by severity (earlier
preterm carries higher risk than later preterm delivery)
and increase with multiple complications (such as pre-
term preeclampsia or preterm SGA) or recurrent com-
plications [61]. All told, between 25 and 35 % of women
will experience at least one pregnancy complication dur-
ing their reproductive life course [12]. Yet studies of
CVD do not routinely collect detailed data on women’s
reproductive histories. There are three main sources of
data on pregnancy history: maternal recall, birth registry,
and medical record. Each has its advantages and disad-
vantages, depending on the age of women studied and
other contextual factors.
Medical record
Medical records remain the “gold standard” for charac-
terizing a woman’s pregnancy history. Yet they have sev-
eral drawbacks, including the expense of collecting and
abstracting records. Primary among these is the difficulty
of obtaining prenatal records for older cohorts of
women, i.e., women assessed after age 60 who had preg-
nancies in their twenties, who are at the highest risk of
CVD events over the next few years. It can be challen-
ging to retrieve 40-year-old records, but this challenge
should be reduced in the future with the use of elec-
tronic medical records.
A second difficulty is that some pregnancy complica-
tions, such as preeclampsia or the indications for an in-
duced labor, may be recorded in part in the outpatient
prenatal setting and in part in the labor and delivery re-
cords of hospitals. Finally, obstetric practice in the de-
tection, definition, and recording of details regarding
pregnancy complications has changed over time. For ex-
ample, standardized testing for gestational diabetes was
not routine in the USA until the 1970s, the criteria for
preeclampsia and gestational diabetes have evolved over
the years, and the basis of gestational dating has shifted
from menstrual dating to fetal ultrasound examination.
These variations in practice create challenges both for
abstracting medical records for primary exposure data
and for deriving a consistent definition for validation
studies of birth registry data and maternal recall data. A
priority goal of practical investigation is to optimize data
collection of pregnancy complications relative to future
CVD.
Birth registries
The vast national birth registries that were established in
the 1960s and 1970s have been the foundation of our
understanding of the links between pregnancy history
and CVD. In Scandinavia, the use of a national health
identification number permits the broad-scale linking of
pregnancy history to CVD hospital admissions and mor-
tality data [62]. The national registries have several ad-
vantages: population representativeness, upwards of
40 years of archived data collection, and ease of elec-
tronic data access. However, like medical records, they
are subject to changes in medical definitions and prac-
tice over time. Most, if not all, studies validating birth
registry data on variables such as preeclampsia, gestation
length, or neonatal birth weight (used to define SGA
and large for gestational age or LGA) show that most of
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these variables are recorded with reasonable accuracy
[63, 64]. Other variables contained in birth registries and
which would require clinicians or clerks to review pre-
natal records, such as gestational weight gain, may be
less reliable. The chief drawback of relying exclusively
on registry data is a usual lack of data on important co-
variates such as cigarette smoking during pregnancy or
body mass index before pregnancy, variables which may
be better collected via medical record or maternal recall.
Maternal recall
Given the lack of availability of medical records or the
limited data fields in birth registries, investigators may
wish to query mothers about their pregnancy histories.
Indeed, for many pregnancy variables, maternal recall
may be a truer “gold standard” than often-incomplete
medical records. This may be particularly true of lifestyle
factors such as smoking or drinking alcohol during preg-
nancy. More debatable is the ability of women to recall
salient clinical details. For example, a recent review of
studies of maternal recall of preeclampsia showed mod-
est sensitivity and low predictive values of positive ma-
ternal recall compared with medical records, though
specificity was high [65]. Clearly, the accuracy of mater-
nal recall depends heavily on the degree of clinical
information communicated to the mother. Currently,
clinicians may share more clinical information with pa-
tients than they did 40 years ago but retention of the in-
formation if only verbal may not be accurate. The
quality of maternal recall depends on exactly how
women are asked about their pregnancy complication
history [66, 67]. Finally, like any exposure subject to mis-
classification, there are methods with which to adjust
exposure-disease associations for exposure misclassifica-
tion, where validation studies exist to quantify the de-
gree of misclassification [68]. There is a need for some
standardization and written documentation provided to
the mother regarding salient clinical features of the preg-
nancy that may impact her future CV risk.
Each study will have to take into account the best ways
to collect data on pregnancy history, depending on the
age of their cohort and the availability and quality of re-
cords and registries. The HUNT studies—a longitudinal
series of clinical CVD exams in Norway—have been able
to link registry data to the clinical examinations [69].
The Nurses’ Health Studies 2 has queried participants
directly about pregnancy complications and is con-
ducting medical record validation of this maternal re-
call [65, 70]. Other studies, such as the Framingham
Heart Study [71], might combine participant recall with
data from the electronic Massachusetts birth certificate.
There may be pregnancy cohorts designed to study
pregnancy complications, such as the US Collaborative
Perinatal Project [72], that might be followed for CVD
events or more recent pregnancy cohorts that can be
followed for the emergence and detailed phenotyping of
CVD risk variables such as vascular function. A short vali-
dated questionnaire may be a starting point to standardize
these data collections [67].
One emerging risk of pregnancy relates to persistent
fetal microchimerism (i.e., the persistence of fetal cells in
the mother throughout life). During pregnancy, fetal and
maternal cells pass across the placenta from the fetus to
the mother and vice versa. These stem cells persist in
the blood or tissues for decades or for the entire life of
the individual [73]. Male fetal progenitor cells persist in
maternal blood for as long as 27 years postpartum [74].
Microchimeric cells could have a deleterious role,
inducing autoimmunity, inflammation, and neoplastic
diseases. On the other hand, the stem cells could con-
tribute to tissue repair and regeneration. Whether the
sex of the fetal cells left behind in the mother plays a
role in determining whether fetal microchimerism is
more likely to be beneficial or harmful has not yet been
clearly determined; however, it is hypothesized that HLA
incompatibility may trigger a variant of chronic host ver-
sus graft disease akin to what is often seen in transplant
patients [75, 76]. For example, maternal cells were found
in the cardiomyocytes of male fetuses who developed
neonatal heart block [77] and women who developed
preeclampsia were much more likely to develop fetal
microchimerism during late gestation and to have higher
concentrations of fetal cells than those with uncompli-
cated pregnancy [78].
Ultimately, pregnancy history—including the preg-
nancy complications, spontaneous abortion, stillbirth,
and fertility—is likely to give us new insight into sex dif-
ferences in CVD. The results may prove to be clinically
useful tools for illuminating new therapies and identify-
ing the many women who might benefit from CVD
preventive interventions and care tailored to their repro-
ductive history.
PCOS and other syndromes with altered ovarian function
Polycystic ovary syndrome (PCOS) is a common condi-
tion that affects approximately 5 % of women of repro-
ductive age in the USA [79, 80] and is estimated to cost
$4 billion annually in health-care costs [81]. Women
with PCOS ovulate irregularly and can have difficulty be-
coming pregnant. The condition is characterized by in-
sulin resistance and hyperandrogenemia of ovarian and
possibly adrenal origin. Other organs affected by PCOS
include the brain, pancreas, liver, muscle, blood vascula-
ture, and fat [82]. In addition to reduced fertility, PCOS
women have a higher incidence of diabetes, acne,
obesity, hirsutism, alopecia, and polycystic ovarian
morphology on ultrasound that also corresponds to
higher anti-Mullerian hormone (AMH) levels and
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increased oocyte count. Women with PCOS are often
insulin resistant and, as a consequence, may have high
insulin levels, with increased risk for type 2 diabetes,
high cholesterol, and high blood pressure [83]. The
underlying insulin resistance is exacerbated by weight
gain, obesity, and age, and women with PCOS develop
metabolic syndrome earlier than ovulatory women of
comparable obesity [84–87].
There remains incomplete consensus of the definition
of PCOS. There are three overlapping criteria for this
disorder: (1) the NIH criteria developed in 1990 at a
NIH conference held to create both a working definition
of the disorder and diagnostic criteria [88]; (2) the
Rotterdam Criteria developed at a consensus workshop
in 2003 [89]; (3) the Androgen Excess and PCOS (AE-
PCOS) criteria developed in 2006 by the AE-PCOS
Society [90]. All three criteria include clinical or bio-
chemical signs of hyperandrogenism and ovarian dys-
function (chronic anovulation), while polycystic ovarian
morphology is included as part of the syndrome for the
Rotterdam and AE-PCOS criteria. Notably, routine med-
ical records typically lack sufficient details to correctly
identify PCOS, and self-reported PCOS was found to be
inaccurate in the WISE study.
While the etiology of PCOS is multifactorial and in-
volves excess androgen secretion by ovaries and ad-
renal glands (primarily androstenedione), genetic,
epigenetic factors, and environmental factors, such as
insulin resistance/diabetes and obesity, there is insuffi-
cient robust prospective data to clearly determine
whether these abnormalities increase the incidence of
cardiovascular events or other diabetic complications
[91, 92]. Some studies have found evidence of greater
subclinical atherosclerosis in women with PCOS com-
pared to control cases as evidenced by increased
prevalence of coronary calcium [93–95] as well as increase
in carotid intima-medial thickness [96, 97]. However,
these studies include relatively small numbers of women
and longitudinal data are not available. Capture of
data that could characterize this condition (including
ovarian dysfunction and clinical or biochemical signs
of hyperandrogenism, for example) in women partici-
pating in longitudinal studies designed to evaluate
cardiovascular outcomes could be extremely useful
and a cost-effective way to increase the scientific un-
derstanding of the chronic CVD effects of PCOS. Be-
cause there are limited data linking the general
categorization of PCOS with the etiology or preva-
lence of clinical CVD in women, specific investigation
in this area is needed.
Acquired, stress-induced, ovulatory disruption is the
most prevalent cause of estrogen deficiency in premeno-
pausal women and is discussed in detail above in
“Methods for characterizing gonadal function” section.
Berga et al. have showed that women with PCOS are
also hypoestrogenic but not hypercortisolemic. Thus, it
is important to identify the etiology of the hypoestrogen-
emia relative to the development of reliable and repro-
ducible CV risk management strategies for women [98].
Psychosocial issues
The lifetime prevalence of depressive disorders in
women is approximately double that of men [99]. The
incidence of depression in women is highest from pu-
berty onward and decreases after menopause [100], with
the exception of an additional spike during perimeno-
pause [101–104]. Currently, it is not clear what causes
this sex difference in mood-related disorders.
A biological susceptibility hypothesis has been sug-
gested to account for sex differences in the prevalence
of mood disorders [105, 106]. This hypothesis posits
that there is a disturbance in the interaction between
the hypothalamic-pituitary-gonadal (HPG) axis and
other neuromodulators in women, and the neuroendo-
crine rhythmicity related to female reproduction is
vulnerable to change and sensitive to psychosocial, en-
vironmental, and physiological factors [107, 108].
Thus, premenstrual dysphoric disorder (PMDD), post-
partum depression (PPD), and mood disorders associ-
ated with perimenopause/menopause may all be related
to hormone-modulated changes in neurotransmitter
function [108] and should be evaluated for their relation
to CVD [105, 106].
Neurotransmitter systems involved in the control of
mood and behavior include the following: glutamate,
gamma-aminobutyric acid (GABA), acetylcholine (ACh),
serotonin (5-HT), dopamine (DA), noradrenaline (NA),
and neuropeptides. Sex steroids modulate the produc-
tion, uptake, and clearance of these neurotransmitters.
Declining levels of estrogen in women have been as-
sociated with postpartum and post-menopausal de-
pression, and the cyclical variations of estrogens and
progesterone may be what triggers premenstrual symp-
toms in women [109].
Estrogen has been described as a 5-HT, NA, and ACh
agonist and also modulates DA2 receptors [110–114].
The influence of the reproductive life cycle of women,
specifically the impact of hormonal fluctuations during
puberty, during the menstrual cycle, during pregnancy
and postpartum, and during the perimenopause period
on mood may be significant. Accordingly, age and repro-
ductive status should be included in mood disorder clin-
ical study and trial designs.
As mood disorders occur in both women and men,
the assumption is that there must be a unified basis for
their development. This common underlying cause is
believed to be related to genetic predisposition. Mul-
tiple stressful life events cause biochemical changes in
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numerous neuroendocrine and neuroanatomical systems.
As genetics determine in part how one interprets and
responds to stressful life events, one may be genetic-
ally predisposed to respond in a way that leads to the
development of mood disorders. The higher preva-
lence of mood disorders in women could be explained
by an increased exposure to stressful life events, an
increased vulnerability due to genetic predisposition
to these events, modulation of the neuroendocrine
system by fluctuating gonadal hormones, or a com-
bination of these factors [115]. Accordingly, collection
of stressful life events and reproductive/hormonal sta-
tus is important for mood disorder clinical study and
trial design.
Several validated and user-friendly instruments are
available for the assessment and measurement of depres-
sion, anxiety, PTSD, and a history of childhood trauma.
These are summarized below.
Depression
The Center for Epidemiologic Studies Depression Scale
(CES-D) [116] is a self-report measure of depressive
symptoms. The temporal stability, the specific depres-
sion severity, and factor structure of the CES-D are well
established. In particular, this scale identifies negative ef-
fect, anhedonia, and somatic symptoms [117–119]. The
Hamilton Rating Scale for Depression (HRSD) [120] is
by far the most commonly used clinician-rated de-
pression scale. Its reliability has been established over
a period of five decades [121], and it has also been
used in most studies assessing depression in cardiac
patients [122, 123]. The Beck Depression Inventory (BDI)
[124, 125] is a self-report assessment of depression tool. It
is extremely popular amongst general practitioners and is
worldwide the most used self-rating scale measuring
depression [126]. Visual Analogue Scales (VAS) and
their clinical applications have been established in
several medical fields including depression, pain, and
premenstrual mood symptoms to name a few [127–129].
As a self-rating instrument, VAS has been used to meas-
ure a variety of subjective social and behavioral phenom-
ena; it is quick, user-friendly, literacy neutral, and in the
case of depression and/or anxiety, can serve as a simple
screen [130].
The two-question case-friendly instrument for de-
pression is as good as six previously validated longer
questionnaires in detecting depression in primary care
[123, 131]. It asks the following:
1. “During the past month, have you often been
bothered by feeling down, depressed, or hopeless?”
2. “During the past month, have you often been
bothered by little interest or pleasure in doing
things?”
The importance of assessing fluctuations in mood
symptoms as a risk factor for CVD seems to be even more
relevant in patients with bipolar disorder [132–135] as
well as in dysthymia [136].
Anxiety
The State-Trait Anxiety Inventory (STAI) is a self-rating
instrument asking about current/recent symptoms of
anxiety (state) as well as how anxious the person is in
general (trait) [137, 138]. It is especially helpful in
treatment/follow-up studies with a focus on change over
time [139, 140]. Another appropriate self-rating measure
is the Generalized Anxiety Disorder (GAD) seven-item
scale developed to detect GAD in primary care popula-
tions [141, 142].
PTSD
Several questionnaires are available for assessing PTSD.
The one that includes both current and lifetime symp-
toms is the Clinician-Administered PTSD Scale (CAPS-1)
[143]. It can be administered by both experienced clini-
cians and trained paraprofessionals. A more specific in-
strument the Harvard Trauma Questionnaire (HTQ)
[144] measures torture, trauma, as well as PTSD.
Childhood trauma
The Childhood Trauma Questionnaire (CTQ) is the
most widely used screening tool for childhood emo-
tional, physical, and sexual abuse as well as emotional
and physical neglect [145–148].
Physiological research
There are important physiological sex differences in
CVD with implications for outcomes and therapies, in-
cluding coronary microvascular dysfunction, heart fail-
ure with preserved ejection fraction (HFpEF), Takotsubo
cardiomyopathy, mortality due to drugs such as digoxin
and QT-prolonging medications, and post-myocardial
infarction (MI) depression, to name a few [15, 149].
A mounting literature documents important sex dif-
ferences in pharmacology, including beta blockers,
angiotensin-converting enzyme (ACE) inhibitors, and
chemotherapeutic agents that have cardiovascular tox-
icity [150]. Accordingly, it is useful to examine the
spectrum of physiological mechanisms (i.e., autonomic,
metabolic, hormonal structural, and endothelial) for CVD
that may differ between women and men, in order to
most appropriately design sex-specific clinical studies
and trials.
Coronary microvascular dysfunction
Up to 40 % of women with signs and symptoms of
myocardial ischemia presenting for invasive coronary
angiography have no obstructive epicardial CAD. These
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women have been considered “low risk,” yet data ob-
tained from angiographic studies demonstrate that this
group includes a subgroup of patients at higher risk of
adverse cardiac events [151]. Recent studies with coron-
ary computed tomographic angiography confirm these
findings in women [152, 153] and demonstrate an in-
creased frequency of coronary vasomotor dysfunction in
these women with evidence of ischemia but no epicar-
dial coronary disease [34], consistent with coronary
microvascular dysfunction. In addition, the threshold for
diagnosis of impaired coronary flow reserve may differ
in women and men [34, 154]. Recent studies indicate
that coronary microvascular disease is also prevalent in
men and impaired coronary flow reserve is a predictor
of major adverse cardiac events in both men and women
[155]. Ongoing investigation is addressing sex-specific
mechanistic pathways for CVD in women, including
traditional CVD risk factors, inflammation, and oxidative
stress, leading to coronary vasomotor dysfunction and
microvascular coronary dysfunction [156–160].
Traditional CVD risk factors
A large body of evidence supports the role of traditional
CVD risk factors with endothelial-dependent dysfunction
and an associated adverse prognosis in women [34, 161].
However, non-endothelium-dependent microvascular
dilation appears to be involved in functional and structural
alterations that lead to impaired coronary flow reserve
with aging [162], hypertension [163, 164], diabetes
[165, 166], dyslipidemia [167, 168], and insulin resist-
ance [169]. Adenosine increases coronary flow pre-
dominantly by non-endothelium-dependent mechanisms
via receptors on microvascular smooth muscle cells to
modulate intracellular Ca2+ [170], while flow or acetylcho-
line results in vasodilation by endothelium-dependent
mechanisms [34]. Because coronary microvascular dys-
function appears to be more prevalent in women, these
findings support that clinical study and trials should in-
corporate sex-specific measures and thresholds in clinical
study and trials.
Diabetes mellitus
Diabetes mellitus is a relatively greater risk factor for
CVD in women compared to men [161, 171]. Diabetes is
associated with microvascular dysfunction in noncardiac
organs such as the eye, kidney, and brain. Chronic
hyperglycemia is associated with significantly reduced
endothelium-dependent and endothelium-independent
coronary vasodilator function [172]. There is evidence
implicating similar adverse effects from insulin resist-
ance or hyperinsulinemia [173] while interventions aim-
ing at improving insulin sensitivity improve endothelial
function and decrease myocardial ischemia in patients
with no obstructive CAD [173]. However, other studies
demonstrate that hyperinsulinemia or insulin resistance
is not associated when other confounding factors are ex-
cluded [174]. Because many of these studies have not
been conducted specifically in women, further investiga-
tion exploring the mechanisms underlying potential sex
differences in metabolism, diabetes, and CVD is needed
including studies of the sex-specific efficacy of pharma-
ceuticals to manage insulin resistance and their potential
to interact with estrogen responsiveness to modulate
CV risk.
Chronic inflammation
Women suffer disproportionately from autoimmune dis-
orders compared to men. A rise in C-reactive protein
(CRP) is noted in girls but not in boys at puberty [34].
High levels of high sensitivity CRP (hsCRP), a marker of
low-grade chronic inflammation, were associated with
increased frequency of ischemic episodes, detected by
ambulatory ECG, in adults [175]. Inflammatory pro-
cesses are associated with increases in oxidative stress.
In patients with systemic lupus erythematosus (SLE),
who are predominantly female [176], there is a 44 %
prevalence of coronary microvascular dysfunction. These
observations suggest that chronic inflammation related
to selected endothelial cell activation may contribute to
the microvascular abnormalities in SLE [177]. Investiga-
tion is needed to further explore sex-specific immune re-
sponse, for example, as measured by inflammatory
cytokines, and whether this response is affected by hor-
monal status or other sex-specific variables.
Novel cardiovascular risk factors
Overall, traditional CVD risk factors associated with cor-
onary microvascular dysfunction account for <20 % of
the observed variability in WISE women [178]. Therefore,
other, as yet unidentified, factors must primarily account
for non-endothelium-dependent coronary microvascular
reactivity. Promising candidates include, but are not
limited to, sex differences in the cardiac autonomic
nervous system [179], regulation of nitric oxide me-
tabolism and inflammatory cytokines, polymorphisms
in estrogen or androgen receptors, and alterations in
the expression or production of local vasoactive sub-
stances and their regulators such as angiotensin II,
endothelin, vasopressin and their metabolites, regula-
tors of the cyclooxygenase pathway, the reactive inter-
mediates of that pathway, and associated intracellular
signaling pathways, as well as steroid hormones as
discussed above [180]. Additional investigations re-
garding physiological sex differences in the gut micro-
biome, infections, and chronic inflammatory disease,
such as rheumatoid arthritis, which preferentially im-
pact women, and sex-specific influence of periodontal
disease, are needed.
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Biomarkers
Clinically, cardiovascular biomarkers are substances that
are measured most typically in the bloodstream when
CVD is present and help diagnose, risk stratify, monitor,
and assist in the management of people with suspected
acute coronary syndrome (ACS), acute MI [181], and
heart failure.
In 2007, the National Academy of Clinical Biochemistry
(NACB) and International Federation of Clinical
Chemistry (IFCC) committee recommended that sex-
specific reference limits should be used in clinical
practice for some cardiac biomarkers [182], yet to our
knowledge, most clinically used assays and laborator-
ies fail to do this. The failure to establish sex-specific,
clinically applicable cardiac biomarker thresholds in
men and women may contribute to the under-
diagnosis of CVD in women, which in turn likely
contributes to lower levels of treatment and resultant
elevated death rates.
The most commonly used biomarkers in CVD stratifi-
cation, cardiac troponin I (cTnI), and cardiac troponin T
(cTnT) have been shown to have significantly different
mean concentrations between men and women, suggest-
ing the need for establishment of sex-specific ranges
[183]. In a 2015 study, Shah et al. [184] reported that
when the current practice threshold for cTnI of 50 ng/L
was utilized, men were twice as likely as women to be
given a diagnosis of myocardial infarction (MI) despite a
similar proportion of men and women reporting chest
pain and demonstrating electrocardiographic changes.
Using a high sensitivity assay with sex-specific diagnostic
thresholds (34 ng/L for men, 16 ng/L for women) dou-
bled the diagnosis of MI in women, such that the diag-
nosis proportion was now similar to men. Subsequently,
they found that the women identified using high sensi-
tivity cTnI sex-specific thresholds had the highest risk of
mortality or recurrent MI, indicating that these women
can potentially greatly benefit from reclassification and
treatment [184]. These data combined with the many
other CVD biomarkers used clinically as well as for re-
search purposes [185] strongly supports the use of sex-
specific biomarker thresholds in guidelines, practice, and
research.
Heart failure with preserved ejection fraction
Heart failure has emerged as a new CVD epidemic re-
lated in part to effective therapies for acute coronary
syndromes and myocardial infarction that have reduced
ischemic heart disease mortality but have increased the
number of patients living with ischemic cardiomyopathy.
In addition, heart failure is prevalent in older individuals,
a growing segment of the population. However, half of
patients hospitalized for heart failure have normal left
ventricular ejection fraction [186–188]. Heart failure
with preserved ejection fraction (HFpEF) has emerged as
the dominant form of HF in aging populations [188, 189].
In a US Medicare population, women have a 71 % higher
prevalence of HFpEF than men independent of clin-
ical conditions that could result in pressure overload,
such as hypertension or renal insufficiency [190].
HFpEF (defined as left ventricular end-diastolic pres-
sure (LVEDP) >16 mmHg with normal ejection frac-
tion [191]) was identified in 67 % of clinically stable
outpatients with unexplained dyspnea, of whom 75 %
were females [192]. Echocardiographic and brain
natriuretic peptide (BNP) are used to establish a diag-
nosis of HFpEF. However, up to 30 % of patients who
meet all other criteria for HFpEF may have normal
BNP levels. The variables predictive of normal BNP
in setting of HFpEF include being female, obese, and
coronary artery disease [193]. LVEDP is typically mea-
sured in resting and overnight-fasting conditions and
may underestimate the true prevalence of LV diastolic
dysfunction as studies have demonstrated that assessment
during stress increases detection of HFpEF [194].
There is currently no effective therapy that has been
shown to reduce mortality in patients with HFpEF. This
may be due in part to under-representation of women in
heart failure clinical trials and to a lack of understanding
of sex-specific heart failure pathophysiology. Cardiac re-
modeling differs between men and women [195, 196],
and there appear to be differences in the signaling path-
ways regulating myocardial hypertrophy [197–199].
Clinical and basic science studies and trials for HFpEF
must be designed with these issues in mind to include
women and the elderly, as well as to study sex-specific
mechanistic pathways.
Takotsubo cardiomyopathy (stress cardiomyopathy)
Transient systolic and diastolic dysfunction occurring in
the absence of coronary atherosclerotic disease was first
described in 1990 in Japan. The disorder has a signifi-
cant female preponderance. The International Takotsubo
Registry published data from 25 cardiovascular centers
in nine countries, including Europe and USA, showing
that 89.8 % of patients were women with a mean age of
66.8 years [200]. Patients frequently present with chest
pain, dyspnea, and less commonly, syncope. Physical
triggers (including acute respiratory failure, post-
surgical/fracture, central nervous system condition, and
infections) were present in 36 % of patients, emotional
triggers (including grief/loss, panic/fear/anxiety, inter-
personal conflict, and anger/frustration) were present in
27.7 % patients. No evident triggers were present in
28.5 %. Neurologic or psychiatric disorders were present
in 57.8 % of patients with Takotsubo cardiomyopathy as
compared to 27.5 % of patients with acute myocardial
infarction. It is not understood why there is such a sex
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difference in this disorder. It has been proposed that this
may be due to sex differences in interactions between
vagal-sympathetic activity and sex hormones [201].
Clinical trials
Death due to CVD in females emerged rapidly as an epi-
demic in 1984 and persists today [202, 203] despite an
overall decline in CVD death rates starting in the 2000s.
Both an excess of death due to CVD, and an absence of
understanding of the root causes of CVD in women, re-
mains. Recommendations to improve the evidence base
for women are listed in Table 2 and discussed further
below.
Recruitment, enrollment, and retention of women
Women (minority women in particular) are underrepre-
sented in cardiovascular clinical trials [204] (Fig. 2).
Basic and clinical research often ignores the possibility
of sex-related differences when designing and interpret-
ing studies. Inclusion of women and sex-specific report-
ing of outcomes in clinical research remains a significant
concern. An initial review of the newly mandated
Federal Drug Administration (FDA) snapshots demon-
strates that newly approved drugs include approximately
only one-third women subjects [205]. Of great concern
is that a majority of medications withdrawn following
FDA approval are due to unanticipated adverse effects in
women [206].
In 1986, the National Institutes of Health (NIH) estab-
lished a policy for inclusion of women in clinical re-
search, and the 1987 NIH guide encouraged the
inclusion of minorities in clinical research studies. Con-
gress transformed what previously had been policy into
Public Law in the NIH Revitalization Act of 1993 (PL
103-43), which reinforced existing NIH policies but with
four major differences, including (1) inclusion of women
and ethnic minorities, (2) valid representation of same,
(3) precludes cost exclusion, and (4) initiates recruitment
and retention activities (Table 3). Subsequent activity in-
cluded the establishment of a NIH tracking and inclu-
sion committee as a monitoring group because the 1990
General Accounting Office (GAO) found that NIH pol-
icy on inclusion was inconsistently applied and had not
been well communicated or understood within NIH or
the external research community. Additional actions
were implemented in 2001 and included (1) conversion
of guidelines regarding inclusion of women and minor-
ities into policy; (2) new terms and conditions for phase
III clinical trials; (3) incorporation of these into NIH
solicitations, applications, and contracts; and (4) incorp-
oration into application reviews. As part of the continu-
ing implementation and monitoring activities, a new
enrollment/recruitment form that documented subjects’
gender became mandatory in May 2005 and required
the revised categories to be used when reporting racial
and ethnic data. A 2011 monitoring compliance report
details the population analysis data required for both
extramural and intramural research [207]. Thus, al-
though the NIH Guidelines are not new and continued
monitoring of adherence to the NIH policy is underway,
the numbers of women in CVD clinical trials along-
side men remains low. In October 2015, the General
Accounting Office reported its findings on women’s
participation in NIH-funded clinical trials as a result of a
performance audit from September 2014 to October 2015
[208]. The GAO reported improvement in inclusion of
women over the past two decades. However, it was recom-
mended that the NIH provide more detailed institute and
center level enrollment data and examine approaches for
aggregating more detailed enrollment data at disease and
condition level and to collect data on monitoring and
reporting plans for sex-difference analyses.
Development of strategies to improve the quality of
health care for women with CVD has been identified
and recommendations are made [16]. Key components
to improve quality care are depicted in Fig. 3 and include
Table 2 Recommendations to improve the evidence base for
women with CVD [16]
1) Improve trial design
a) Power trials to test heterogeneity in outcomes by sex
b) Explore further such heterogeneity when identified
c) Form a statistics working group to develop alternative statistical methods
2) Better enrollment in trials
a) Increase use of proven recruitment and retention strategies
b) Research to understand sex-related differences in recruitment and
retention of subjects and how to overcome them
c) Employ regulatory and reimbursement strategies
d) Better Centers for Medicare and Medicaid Services coverage of
trial expenses
3) Mandate reporting of primary and secondary results in
clinical trials by sex
a) Journal editors require sex-specific reporting in all primary manuscripts
b) Publish or web post brief secondary presentations and/or papers
on results in women
c) Explore alternative ways to enhance accessibility of new and
existing data for review and for incorporation into meta-analyses
4) Create incentives to enhance the performance of research in
women
a) Alter pre-market investigational paradigm regarding sex-based data
b) Identify business incentives
c) Implement new FDA policies requiring discussion of the impact of
sex before devices or drugs receive approval
d) Consider extensions in patent duration for enhanced pre-clinical
testing of drugs and devices in women
e) Increase awareness of the problem among investigators, industry,
and regulators
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(1) enhance the quantity and quality of evidence-based
medicine to guide care in women through improvements
in trial design, enrollment and retention of women sub-
jects, results analysis and reporting, and better incentives
to perform research in women; (2) provide incentives to
develop better data in women through mandating changes
in the drug and device development and approval pro-
cesses; (3) incorporate specific recommendations for
women into guidelines when data are sufficient; and
(4) apply proven sex-based differences in risk stratifi-
cation, diagnostic testing, and drug usage and dosing
in clinical care [16].
The elderly (dominantly women)
Women constitute the majority of the Medicare popula-
tion and an even greater percentage of very elderly indi-
viduals. Incidence and prevalence of CVD increases with
aging but particularly for women who develop clinical
manifestations of CVD at later age than their male
counterparts (mean age for presenting with ACS for
men 69 years, women 72 years) [202]. Adults age ≥75
comprise fewer than 10 % of the US population yet con-
stitute almost half of all patients with acute coronary
syndromes and over two-thirds of all acute deaths from
coronary disease. Exclusion or underrepresentation of
elderly individuals in clinical trials doubly disadvantages
elderly women, who have the highest incidence, preva-
lence, and adverse outcomes of acute coronary events
[200–211]. Yet, in several large registries and a clinical
trial [212], older patients treated with revascularization
procedures versus medical therapy had a greater risk re-
duction in mortality than those younger than age 65,
despite their multiple comorbidities [213, 214]. Of
importance, age-related pharmacokinetic and pharmaco-
dynamic changes can alter drug dosing, efficacy, and
safety and this is often compounded by polypharmacy
[215, 216] further disadvantaging women. Elderly
women are the group least likely to be referred to car-
diac rehabilitation, where exercise can improve their
functional status and secondary prevention modalities
can be reinforced [217, 218]. Elderly women have the
most adverse outcomes from atrial fibrillation, particu-
larly stroke, yet anticoagulant therapy is paradoxically
underutilized. In the CHA2DS2-VASc score for risk
stratification, age >75, age 65–74, and female sex all de-
fine increased risk [219].
Outcomes of cardiovascular clinical trials emphasize
mortality benefit, with inattention to outcomes valued
by many elderly patients—independence, decreased
symptoms, improved functional capacity, and decreased
hospitalizations. Clinical trials in elderly patients must
Fig. 2 Women are underrepresented in cardiovascular clinical trials [204]
Table 3 NIH Revitalization Act of 1993 (PL 103-43)
The act reinforced existing NIH policies but with four major differences:
1. That NIH ensure that women and minorities be included in all
clinical research
2. That women and minorities be included in phase III clinical trials in
numbers adequate to allow for valid analyses of differences in the
intervention
3. That cost is not allowed as an acceptable reason for excluding
these groups
4. That NIH initiates programs and support for outreach efforts to
recruit and retain women and minorities as participants in clinical
studies
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incorporate indices of physical and cognitive function,
consider comorbidities and polypharmacy, and address
outcomes desired and valued by elderly patients [220].
Data maintenance and reporting by sex
While women have been, and remain under-represented
in clinical trials [204], a great deal of data exist, but are
not available to researchers, caregivers, or policymakers
in that trial results are often not reported by sex [221]
(Fig. 4). Especially in view of requirements for inclusion
of women in clinical trials, several recent studies have
highlighted the importance of such reporting by empha-
sizing the clinical differences between sexes in the re-
































Fig. 4 Number of articles reporting data on women by year [221]
Fig. 3 Cycle of quality to improve the care of women with CVD
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effect profile of pharmacologic agents may differ by sex,
specifically, women are more likely to suffer torsades
de pointes and increased bleeding [225, 226] com-
pared with men. Thus, strong scientific and clinical
concerns suggest encouraging, if not requiring, that
trials and research sponsors be obligated to separately
report data generated in women. Moreover, this could
also be accomplished by a requirement by journal ed-
itors to include sex-specific reporting in all primary
manuscripts.
FDA requirements
In the Food and Drug Administration Safety and
Innovation Act (Public Law No. 112-144) signed into
law 9 July 2012 required demographic data and analysis
of sex, age, race, and ethnicity to be posted in a report
on the FDA website within a year of enactment and an
action plan to be developed. In December 2011, the
FDA issued a “Draft Guidance for Industry and Food
and Drug Administration staff,” on “Evaluation of Sex
Differences in Medical Device Clinical Studies.” This
FDA document addresses the scope of the problem, the
importance of considering sex differences, barriers to
enrollment of women, and recommendations for achiev-
ing representative enrollment. This guide recommends
for the disease or condition for which the device is
intended to treat or diagnose: sex-specific prevalence,
sex-specific diagnosis and treatment patterns; identifica-
tion of proportions of women included in past studies
for the target indications; and identification of any
known clinically significant sex differences in outcomes
related to either safety or effectiveness. The recommen-
dation was that this information be included in the study
and submission documents for (1) new or ongoing stud-
ies, (2) completed studies (marketing application stage),
and (3) post-market studies (PHS 522 PS stage). In
addition, altering pre-market investigational paradigms
regarding sex-based data were encouraged by alignment
of regulatory requirements and enhancement of business
incentives for this purpose [207]. Included among the
paradigms considered was that a discussion about the
impact of sex should be undertaken before devices or
drugs receive FDA approval. Tactics discussed included
(1) inclusion of sex on the checklist for document prep-
aration for FDA-sponsored meetings, (2) mandatory sub-
stantive review of available sex-specific data with each
phase 2 report with obligatory inclusion in meeting
minutes, and (3) amending ICH E3 guidelines. Similar
requirements to tighten FDA regulations for reporting
sex- and gender-based data about new and experimental
medicines and devices were included in the Heart
Disease Education, Analysis and Research, and Treatment
(HEART) for Women Act proposed legislation introduced
to the 112th Congress (2011–2012).
Another suggestion with broad implications was the
consideration of a new policy allowing extensions in pa-
tent duration for additional research in women such as
those granted for new pediatric indications, which have
been highly successful in encouraging research on medi-
cations in children. Advocacy groups were encouraged
to add technical expertise to better address these issues
within their current missions. Finally, strategies to in-
crease awareness of the problem among investigators,
industry, and regulators have been endorsed, including
requiring investigators to complete continuing medical
education on sex differences in disease, multidisciplinary
forums such as those held by the Drug Information
Agency, educational seminars with FDA leadership,
and increased use of existing NIH online educational
materials [16].
Adverse event (AE) and serious adverse event (AE)
reporting
Improving the accessibility of new and existing data
for review and for incorporation into meta-analyses is
needed [227]. AE and SAE data stratified by sex
should be included in the primary or secondary
manuscript and/or available in an appendix to the
primary manuscript. Secondary presentations and/or
papers on results in women or sex comparisons
should be encouraged by conference chairs, editors,
and academic institutions. Alternative ways should
also be explored to make these data publicly available,
such as online appendices. The American Heart Jour-
nal has already taken a public stand in favor of such
reporting [16, 228]. Other novel approaches to im-
prove data availability in women include enhancing
the bioinformatics infrastructure to standardize electronic
clinical data (Clinical Data Interchange Standards
Consortium http://www.cdisc.org) to allow tracking of
recruitment, analyzing data across clinical trials that
alone do not have sufficient numbers of women for
meaningful analyses, and analyzing of adverse events.
Recently, the FDA has embarked on an ambitious
bioinformatics modernization effort that includes an
effort to harmonize with the standards being used in
exchange of Electronic Health Records, which may
improve our ability to detect important sex differ-
ences [227].
Statistical analysis: how to analyze by sex, what needs to
be considered to analyze in sex-specific fashion, analyze
adjusting for sex, and analyzing for interaction by sex
A variable for male or female is usually collected in clin-
ical study datasets. We advise that a clear definition of
the term is provided for each study. Sex is the biologic
variable and gender a self-declared variable encompass-
ing psychosocial and cultural attributes. A primary
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Table 4 Variables to consider in studies of woman’s cardiovascular disease and risk




Smoking status Prior, current
History of hypertension Blood pressure
Blood lipids (HDL, LDL, triglycerides)
Diabetes, glucose, insulin,
Inflammation: hsCRP
History of chronic inflammatory disease (Asthma, inflammatory rheumatologic disease, migraine, inflammatory
bowel disease)
Prior cancer Type (breast, etc), chest radiation, chemotherapy
Prior CVD Angina, myocardial infarction, cerebrovascular disease, coronary
revascularization procedures, peripheral arterial disease, heart failure
Sex-specific or less conventional risk factors
Pregnancy-related variables Questions to ascertain information
Parity Number of pregnancies lasting >20 weeks
Fetal deaths Number of miscarriages <20 weeks, stillbirths
History of preeclampsia Have you ever had preeclampsia or toxemia?
History of gestational hypertension Have you ever had gestational hypertension (pregnancy-related high
blood pressure or pregnancy-induced hypertension)?
History of gestational diabetes Have you ever had gestational diabetes (new onset diabetes
of pregnancy)?
Offspring birthweight and gestation length (when assessed
together, this allows calculation of small-for-gestational age and
large-for-gestational age)
Birthweight of each child (lbs and ounces) and gestation length:
Low birthweight Have you ever delivered an infant weighing less than 5 lbs 8 oz
(less than 2500 g)?
Macrosomia (indicative of gestational diabetes) Have you ever delivered an infant weighing more than 10 lbs
(more than 4500 g)?
Menopause-related variables Questions to ascertain information
Menopausal status Have your natural menstrual periods ceased permanently?
(No; Yes—no menstrual periods; Yes—had menopause but now
periods induced by hormones; Not sure)
At what age did natural periods stop?
For what reason? (natural; surgical; radiation or chemotherapy; others)
Did you have a hysterectomy, if so at what age
Did you have removal of ovary (unilateral or bilateral) and if so,
at what age
Current use of hormones Are you currently using:
- Oral contraceptives,
- Transdermal hormone therapy
- Vaginal hormone therapy
Have you ever used these therapies?
Menstrual regularity What is the current usual pattern of your menstrual cycles
(when not pregnant, lactating, or on the pill): extremely regular
(no more than 1–2 days before or after expected); very regular
(within 3–4 days); regular (within 5–6 days); usually irregular;
always irregular; no periods
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consideration for sex-specific analyses is that if sex or
gender is an a priori secondary analysis, then the en-
rolled cohort of women should be sufficiently powered
for comparative analysis of the primary aim. Without
this a priori planning, all reported sex and gender com-
parisons should include a post hoc statistical power cal-
culation. In treatment trials, differential procedural
effectiveness and complications as well as adherence to
guideline-directed lifestyle and medical therapy should
be reported as clinical management recommendations
are often suboptimal among women as compared to
men. Appendices reporting a more detailed analysis by
sex/gender, including subsets (e.g., younger women)
should be included for all major observational and clin-
ical trials. Consideration should also be given to targeted
population strata of women of diverse race and ethni-
city as these subsets report the highest morbid and
fatal event rates. In many cases, adjusted analyses are
presented that control for clinical and comorbid co-
variates that may minimize sex differences. It is rec-
ommended that absolute rates of morbid and fatal
event rates also be included with adjusted analyses.
Care should be taken when women are matched to
subsets of men by a priori chosen criteria (e.g., pro-
pensity matching techniques). Matching women to
men may select a subset of atypical females and
minimize unique sex-specific differences. If matching
is performed, details as to how the selected women
compared to the whole subset of females should be
provided as well as additional sex stratified analyses.
Table 4 Variables to consider in studies of woman’s cardiovascular disease and risk (Continued)
Psychosocial Variables Questions to ascertain information
History of violent abuse Before age 18, did any adult in your family:
- Push, grab, or shove you
- Kick, bite, or punch you
- Hit you with something that hurt your body
- Choke or burn you
- Force you into sexual activity by threatening you, holding you down,
or hurting you in some way when you did not want to
- Physically attack you in some other way
Responses: never; once; a few times; more than a few times
Since age 18, has anyone (repeat above)
Current depression screener Clinical screener recommended by USPSTF:
- Over the past 2 weeks, have you felt down, depressed, or hopeless?
- Over the past 2 weeks, have you felt little interest or pleasure in
doing things?
Antidepressant use (e.g., Prozac, Zoloft, Lexapro, Pamelor, Cymbalta)
More formal screening tools include:
- Beck Depression Inventory
- General Health Questionnaire
- Center for Epidemiologic Study Depression Scales (CES-D)
- Patient Health Questionnaire PHQ 9 (Quick Depression Assessment)
History of depression screener In your lifetime, have you ever had 2 weeks or longer when nearly
every day you felt sad, blue, or depressed for most of the day?
Did you ever tell a doctor or mental health specialist that you were
feeling depressed?
Has a health provider ever diagnosed you with depression?
Current psychosocial stress Short version of Cohen Perceived Stress Scale:
In the last month, how often have you
- felt that you were unable to control the important things in your life?
- felt confident about your ability to handle your personal problems?
- felt that things were going your way?
- felt difficulties were piling up so high that you could not overcome them?
Reponses: never; almost never; sometimes; fairly often; very often
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Conclusions
Efforts to develop and use sex-specific information re-
garding women have increased over the last two de-
cades, and while there is still a great need for more data,
the evidence base has increased. We encourage investi-
gators to consider these variables that have impact on
women’s CVD risk and outcomes when designing
studies. Table 4 provides a summary of variables to con-
sider and a sampling of proposed questions to document
pregnancy, menopause, and psychosocial variables. Pro-
grams that involve women across their lifespan should
also consider the participants’ future risk for CVD risk.
Incorporation of sex-specific knowledge into research
strategies is aimed at improving clinical CVD outcomes
and addressing health disparities for women.
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